Evotec SE Q2 2025 Earnings Recap

EVT.DE Q2 2025 August 13, 2025

Get alerts when EVT.DE reports next quarter

Evotec SE reported a 5% decline in total revenues for H1 2025, driven primarily by an 11% drop in the Discovery & Preclinical Development segment, while Just - Evotec Biologics demonstrated strong growth with 16% revenue increase, highlighting the effectiveness of the company's strategic transformation.

Earnings Per Share Miss

$-0.24 vs $-0.13 est.

-93.3% surprise

Revenue Miss

171235000 vs 201625580 est.

-15.1% surprise

Market Reaction

1-Day +0.68%

5-Day -5.04%

30-Day -10.02%

See EVT.DE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total group revenues for H1 2025 reached EUR 371 million, down from H1 2024, with temporary disruptions impacting BMS collaboration.
Just - Evotec Biologics (JEB) achieved significant growth, solidifying its position as a leader in biologics manufacturing.
Initiatives to streamline operations and align organizational structure with strategic goals are underway, aimed at enhancing accountability and performance.
Market conditions remain challenging, particularly in early-stage biotech funding, although signs of recovery are beginning to emerge.
The planned sale of the Toulouse site to Sandoz aligns with Evotec's strategy of focusing on scalable technology in its biologics segment.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit EVT.DE on AllInvestView.

Next Q3 2025